# Implantable System for Remodulin Post-Approval Study

> **NCT03833323** · — · WITHDRAWN · sponsor: **Medtronic Cardiac Rhythm and Heart Failure**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **COMBINATION_PRODUCT:** Implantable System for Remodulin (treprostinil)

## Key facts

- **NCT ID:** NCT03833323
- **Lead sponsor:** Medtronic Cardiac Rhythm and Heart Failure
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Implantable System for Remodulin not commercially approved.
- **Last updated:** 2021-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833323, "Implantable System for Remodulin Post-Approval Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03833323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*